Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):135–139. doi: 10.1097/QAI.0000000000000104

Table 1.

Cases External controls Resistant women

n=162 n=470 n=86
Age 28 (24 – 33) 30 (25 – 35)* 33 (29 – 38)*
Years in sex work prior to enrollment 1 (0.25 – 3) 1 (0.1 – 4) 2 (0.5 – 7)
Years in sex work after enrollment (censored at infection) 1.0 (0.4 – 2.2) 4.8 (2.2 – 8.2)* 13.4 (11.2 – 15.6)*
Calendar year of sample collection 1997 (1995 – 2001) 2000 (1996 – 2005) 1997 (1995 – 2002)
Hormonal contraception in past 70 days, no. (%)
   Oral contraceptive pill 28 (17%) 54 (12%) 0 (0%)*
   Depot medroxyprogesterone acetate 51 (32%) 92 (13%)* 11 (13%)*
   Norplant 3 (2%) 10 (2%) 1 (1%)
   Intrauterine device 4 (2.5%) 9 (2%) 2 (4%)
Sexual risk behavior in past week
   Sex frequency 1 (0 – 2) 1 (0 – 2) 1 (0 – 2)
   Number sexual partners 1 (0 – 1) 1 (0 – 1) 1 (0 – 1)
   Any unprotected sex, no. (%) 43 (28%) 107 (23%) 31 (36%)
Sexual risk behavior averaged over time in cohort
   Average unprotected sex acts per week 0.08 (0 – 0.6) 0.09 (0 – 0.7) 0.1 (0 – 0.7)
STI in past 70 days, no. (%)
   Bacterial vaginosis 85 (52%) 228 (49%) 40 (47%)
   Trichomoniasis 13 (8%) 31 (7%) 9 (11%)
   Cervicitis 35 (22%) 72 (9%) 12 (14%)
   Gonorrhea 16 (10%) 21 (4%)* 2 (2%)
   Genital ulcer disease 8 (5%) 10 (2%) 5 (6%)
   Any 113 (70%) 271 (58%)* 48 (57%)*

Values shown are median (IQR) except as noted.

*

Significantly different than cases, p<0.05